US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma · Dravet Syndrome · Dravet syndrome · STOK
Stoke Therapeutics
Stoke Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Bedford, USA HQ
2017 Founded
205 Employees
Public company Type
STOK · NYSE Ticker
Company details
- Status
- Public
- HQ
- Bedford, USA
- Founded
- 2017
- Employees
- 205
- Programs
- 8
- Drugs
- 4
- Patents
- 14
Stoke Therapeutics pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Stoke Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Stoke Therapeutics in public FDA and regional records.
-
Development asset linked to Stoke Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.
- Target
- cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
- Mechanism
- Phosphodiesterase 3A inhibitor